Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00262015|
Recruitment Status : Unknown
Verified December 2005 by Chiron Corporation.
Recruitment status was: Active, not recruiting
First Posted : December 6, 2005
Last Update Posted : December 6, 2005
|Condition or disease||Intervention/treatment||Phase|
|Meningococcal Disease; Meningococcal Meningitis||Biological: · Meningococcal C conjugate vaccine; Meningococcal A/C Polysaccharide vaccine (partial dose)||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||264 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase IV, Single Center, Open-Label, Controlled, Randomized Study to Evaluate the Memory Response of Children Previously Vaccinated With Chiron Meningococcal C Conjugate Vaccine, Menjugate® and Describe the Kinetic of the Antibody Response and Maturation on Days 2-7 and 28 After Challenge With Pasteur Merieux Meningococcal A/C Polysaccharide Vaccine or Menjugate®|
|Study Start Date :||September 2003|
- To measure immunological memory response to N. meningitidis serogroup C after those who received a partial dose of Meningococcal A/C Polysaccharide vaccine and in subjects who received a dose of Chiron Meningococcal C conjugate vaccine.
- To assess the immunological response to N. meningitidis serogroup C in those challenged with meningococcal A/C polysaccharide vaccine and in those who received a dose of Chiron Meningococcal C conjugate vaccine.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00262015
|University of Oxford, The Oxford Vaccine Group|
|Oxford, United Kingdom, OX3 9DU|
|Principal Investigator:||Andrew J. Pollard, MBBS, FRCPCH, PhD||University of Oxford|